Vaccine immunotherapy for treating cervical cancer in immune suppressed patients
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.
1. A method for treating cervical cancer in a patient, the method comprising:
administering to the patient having cervical cancer an effective amount of a natural cytokine mixture comprising the cytokines IL-1beta, IL-2, IL-6, IL-8, IFN-gamma, and TNF-alpha.
2. The method of claim 1 , wherein the natural cytokine mixture is administered to the patient perilymphatically.
3. The method of claim 1 , wherein the method further comprises:
administering to the patient an effective amount of cyclophosphamide.
4. The method of claim 1 , wherein the method further comprises:
administering to the patient an effective amount of cyclophosphamide, and
administering to the patient an effective amount of a nonsteroidal anti-inflammatory drug (NSAID).
5. The method of claim 1 , wherein the method further comprises:
administering to the patient an effective amount of at least one exogenous tumor antigen.
6. The method of claim 1 , wherein the natural cytokine mixture further comprises GM-CSF and G-CSF.
7. The method of claim 2 , wherein the method further comprises:
administering to the patient an effective amount of cyclophosphamide.
8. The method of claim 2 , wherein the method further comprises:
administering to the patient an effective amount of cyclophosphamide, and
administering to the patient an effective amount of a NSAID.
9. The method of claim 2 , wherein the method further comprises:
administering to the patient an effective amount of at least one exogenous tumor antigen.
10. The method of claim 4 , wherein the NSAID is indomethacin.
11. The method of claim 6 , wherein the natural cytokine mixture is administered to the patient perilymphatically.
12. The method of claim 6 , wherein the method further comprises:
administering to the patient an effective amount of cyclophosphamide.
13. The method of claim 6 , wherein the method further comprises:
administering to the patient an effective amount of cyclophosphamide, and
administering to the patient an effective amount of a NSAID.
14. The method of claim 6 , wherein the method further comprises:
administering to the patient an effective amount of at least one exogenous tumor antigen.
15. The method of claim 13 , wherein the NSAID is indomethacin.
16. The method of claim 11 , wherein the method further comprises:
administering to the patient an effective amount of cyclophosphamide, and
administering to the patient an effective amount of a nonsteroidal anti-inflammatory drug (NSAID).
17. The method of claim 16 , wherein the NSAID is indomethacin.